The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Venetoclax plus idasanutlin for R/R AML: Phase I/II trial
Effective therapies for relapsed/refractory acute myeloid leukemia (AML) remain limited. Here, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase I/II study (NCT02670044) looking to adress this issue, evaluating the use of venetoclax, a BCL2 inhibitor, plus idasanutlin, the MDM2 inhibitor, in R/R AML. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Daver reveals the promising safety, tolerability and efficacy of this combination, with deep and durable response rates.
